Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glutamine (L-glutamine) is a naturally occurring non-essential amino acid that becomes conditionally essential during periods of metabolic stress, such as major surgery, trauma, or chronic illness. It is the most abundant free amino acid in the human body, primarily synthesized and stored in skeletal muscle. Glutamine serves as a critical fuel source for rapidly proliferating cells, including leukocytes and intestinal enterocytes, thereby supporting immune function and gastrointestinal mucosal integrity. In clinical practice, pharmaceutical-grade glutamine is FDA-approved for the treatment of sickle cell disease (to reduce acute complications) and short bowel syndrome (in combination with growth hormone). It is also widely investigated for its ability to stimulate GLP-1 secretion in metabolic disorders, reduce protein degradation in muscular dystrophies, and mitigate wasting in HIV/AIDS and cancer cachexia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glutamine.